Novogen to Hold Investor Briefing in New York

NEW YORK, Feb. 17, 2015 /PRNewswire/ -- Novogen is holding an Investor Briefing in New York on Wednesday 18 February 2015. Novogen Group CEO, Graham Kelly PhD will be outlining the Company's basic, translational and clinical research oncology programs scheduled for the next 2 years, along with the strategies being put in place for funding an anticipated steep growth vector.

Presenting also will be Professor Gil Mor (Yale Medical School) who will review the pre-clinical research leading to the development of Cantrixil, the first chemotherapy specifically designed for the treatment of cancer of body cavities, and Dr Marc Symons (Feinstein Medical Research Institute) who will review the pre-clinical program to bring TRXE-009 into the clinic for the treatment of adult and pediatric primary and secondary brain cancers.

The Briefing also will provide an opportunity to meet some of the Novogen senior executive team. A Q & A session also will be conducted with those executives.

The Briefing is to be held at the Yale Club, 50 Vanderbilt Ave, New York (directly opposite Grand Central Terminal), starting at 2 pm.

All interested parties are invited to attend and are encouraged to register at [email protected] to assist with seating arrangements.

Further information is available on our website http://www.novogen.com.  

For more information please contact:

Forward Looking Statement

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.  The Company has tried to identify such forward-looking statements by use of such words as "expects," "appear," "intends," "hopes," "anticipates," "believes," "could," "should," "would,"  "may," "target,"  "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.  Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, and any other statements that are not historical facts.  Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to events that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to the Company's two proprietary technology platforms, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K.  Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release.  Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

SOURCE Novogen Ltd